OC
ABMD

Oppenheimer & Co’s Abiomed Inc ABMD Stock Holding History

Oppenheimer & Co’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,021
Closed -$367K – 1614
2021
Q4 		$367K Sell
1,021
-1,465
-59% -$495K 0.01% 1143
2021
Q3 		$809K Buy
+2,486
New +$842K 0.02% 821

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Oppenheimer & Co's ABMD Position: Q1 2022 in Review

Oppenheimer & Co sold out of Abiomed Inc (ABMD) in Q1 2022, closing a stake of 1,021 shares — an estimated $367K sold.

Oppenheimer & Co first reported a position in ABMD in Q3 2021 and held it in 2 quarters. The position peaked at $809K in Q3 2021. 500 funds tracked by Wall St. Rank hold ABMD as of Q1 2022.

  • Oppenheimer & Co reported no remaining Abiomed Inc position as of Q1 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 1,021 Abiomed Inc shares in Q1 2022, an estimated $367K.
  • Oppenheimer & Co first reported a position in Abiomed Inc in Q3 2021 and held it in 2 quarters.
  • Oppenheimer & Co's Abiomed Inc position peaked at $809K in Q3 2021.
  • 500 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2022.

Based on Oppenheimer & Co's 13F filing for Q1 2022, filed 12 May 2022.